Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
The feature you requested does not exist. However, we suggest the following feature:

Initiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug Makers Equities

share with twitter share with LinkedIn share with facebook
share via e-mail
06/21/2018 | 01:32pm CEST

Stock Research Monitor: ABBV, AZN, and LLY

LONDON, UK / ACCESSWIRE / June 21, 2018 / If you want a free Stock Review on BMY sign up now at www.wallstequities.com/registration. In today's pre-market research, WallStEquities.com monitors four Major Drug Manufacturers stocks, namely, AbbVie Inc. (NYSE: ABBV), AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Co. (NYSE: BMY), and Eli Lilly and Co. (NYSE: LLY). These companies are part of the pharmaceutical manufacturing sector, which is primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. All you have to do is sign up today for this free limited time offer by clicking the link below.



North Chicago, Illinois-based AbbVie Inc.'s stock finished Wednesday's session 0.24% higher at $98.25 with a total trading volume of 4.68 million shares. The Company's shares have advanced 37.95% over the past year. The stock is trading below its 50-day moving average by 0.84%. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 46.84.

On June 01st, 2018, research firm Piper Jaffray downgraded the Company's stock rating from 'Overweight' to 'Neutral'.

On June 14th, 2018, AbbVie's Board of Directors declared a quarterly cash dividend of $0.96 per share. The cash dividend is payable on August 15th, 2018, to stockholders of record at the close of business on July 13th, 2018.Get the full research report on ABBV for free by clicking below at:



Shares in Cambridge, the UK headquartered AstraZeneca PLC ended at $36.13, up slightly by 0.53% from the last trading session. The stock recorded a trading volume of 1.68 million shares. The Company's shares have gained 4.39% in the previous three months and 4.06% over the past year. The stock is trading 4.57% above its 200-day moving average. Moreover, shares of AstraZeneca, which discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide, have an RSI of 46.77.

On June 19th, 2018, announced that the Company and its global biologics research and development arm, MedImmune, will present 45 abstracts, including seven late-breaking data disclosures from AstraZeneca's Cardiovascular, Renal and Metabolism therapy area, at the American Diabetes Association's 78th Scientific Sessions, which will be held from June 22nd, 2018, to June 26th, 2018, in Orlando, Florida. Gain free access to the research report on AZN at:


Bristol-Myers Squibb

New York headquartered Bristol-Myers Squibb Co.'s stock ended yesterday's session 1.14% higher at $54.25 with a total trading volume of 5.34 million shares. The Company's shares have advanced 3.85% in the past month. The stock is trading 2.47% above its 50-day moving average. Additionally, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 61.07.

On June 14th, 2018, Bristol-Myers Squibb's Board of Directors declared a quarterly dividend of $0.40 per share on the Corporation's $.10 par value Common Stock. The next quarterly dividend will be payable on August 01st, 2018 to stockholders of record at the close of business on July 06th, 2018. The Board also declared a quarterly dividend of $0.50 per share on the Corporation's $2.00 Convertible Preferred Stock, payable on September 04th, 2018, to stockholders of record at the close of business on August 07th, 2018. Signing up today on Wall St. Equities will give you access to the latest report on BMY at:


Eli Lilly

On Wednesday, shares in Indianapolis, Indiana headquartered Eli Lilly and Co. recorded a trading volume of 4.14 million shares, which was above their three months average volume of 3.90 million shares. The stock finished 0.62% lower at $86.28. The Company's shares have advanced 5.44% in the last month, 10.28% in the previous three months, and 4.27% over the past year. The stock is trading above its 50-day and 200-day moving averages by 5.03% and 4.59%, respectively. Furthermore, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 62.24.

On June 08th, 2018, research firm Cantor Fitzgerald initiated an 'Overweight' rating on the Company's stock, with a target price of $100 per share.

On June 18th, 2018, Eli Lilly's Board of Directors has declared a dividend for Q3 2018 of $0.5625 per share on outstanding common stock. The dividend is payable on September 10th, 2018, to shareholders of record at the close of business on August 15th, 2018. Register now for today's free coverage on LLY at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/


For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

Stocks mentioned in the article
ChangeLast1st jan.
ABBVIE -2.33% 95.82 Delayed Quote.1.59%
ASTRAZENECA -2.31% 5255 Delayed Quote.5.04%
BRISTOL-MYERS SQUIBB COMPANY -0.46% 53.955 Delayed Quote.-12.47%
ELI LILLY AND COMPANY -0.14% 86.08 Delayed Quote.2.79%

© Accesswire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
01:32pInitiating Free Research Reports on Bristol-Myers Squibb and Three Other Drug..
10:23aBRISTOL-MYERS SQUIBB COMPANY : - Empliciti Plus Pomalidomide and Low-Dose Dexame..
06/20BRISTOL MYERS SQUIBB : Myers, AbbVie eye new use for myeloma drug Empliciti afte..
06/20BRISTOL-MYERS SQUIBB COMPANY : - China National Drug Administration Approves Cou..
06/20BRISTOL MYERS SQUIBB : Dallas Cowboys Quarterback Dak Prescott, Modern Family St..
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
06/19THE GLOBAL ORGAN PRESERVATION MARKET : Some of the key players in Global Organ P..
06/18BRISTOL MYERS SQUIBB : BMS scores China's first IO approval
06/17BRISTOL MYERS SQUIBB : Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dex..
06/15BRISTOL MYERS SQUIBB : China National Drug Administration Approves Country&rsquo..
More news
News from SeekingAlpha
03:22pNeon Therapeutics Firms Its Plan For $100 Million IPO 
08:00a3 THINGS IN BIOTECH, JUNE 20 : Bristol Burns Up The Myeloma World 
05:59aUnder Armour Is A Winner - Cramer's Lightning Round (6/20/18) 
06/20YOUR DAILY PHARMA SCOOP : TG Therapeutics Phase 2 Results, Geron Positive, Agio .. 
06/19Idera Stock Has Declined Since Failure Of Phase 2 Trial In Rare Disease, But .. 
Financials ($)
Sales 2018 21 740 M
EBIT 2018 5 499 M
Net income 2018 4 486 M
Finance 2018 428 M
Yield 2018 3,00%
P/E ratio 2018 19,17
P/E ratio 2019 16,32
EV / Sales 2018 4,01x
EV / Sales 2019 3,70x
Capitalization 87 677 M
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus HOLD
Number of Analysts 21
Average target price 57,3 $
Spread / Average Target 5,7%
EPS Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Vicki L. Sato Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-12.27%328 751
PFIZER0.00%211 871
NOVARTIS-10.17%188 057
ROCHE HOLDING LTD.-12.19%183 625